Fluorouracil Rx

Indications for Fluorouracil:

Palliative management of carcinoma of the breast.

Adult Dose for Fluorouracil:

Give by IV inj. 12mg/kg once daily for 4 successive days; max 800mg/day. If no toxicity is observed, 6mg/kg are given on the 6^th, 8^th, 10^th, and 12^th days unless toxicity occurs. Maintenance therapy: repeat dosage of 1^st course every 30 days after the last day of the previous course of treatment; or give a maintenance dose of 10–15mg/kg per week as a single dose; max: 1g/week. Poor risk patients: see literature for dose adjustments.

Children's Dose for Fluorouracil:

Not recommended.

Pharmacological Class:

Antimetabolite.

Contraindications:

Poor nutritional state. Depressed bone marrow function. Potentially serious infections.

Warnings/Precautions:

Narrow margin of safety; monitor for toxicity. Consider hospitalization for 1^st course. History of high-dose pelvic irradiation. Previous use of alkylating agents. Widespread involvement of bone marrow by metastatic tumors. Renal or hepatic impairment. Discontinue if signs of toxicity appear (eg, stomatitis, esophagopharyngitis, leukopenia, intractable vomiting, diarrhea, GI ulceration or bleeding, thrombocytopenia, hemorrhage). Monitor WBCs with differential before each dose. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Potentiated by leucovorin.

Adverse Reactions:

Stomatitis, esophagopharyngitis, GI upset, anorexia, leukopenia, alopecia, dermatitis, hand-foot syndrome; others.

Note:

Testing considerations: TS (thymidylate synthase), MSI (microsatellite instability), DPD (dihydropyrimidine dehydrogenase). Formerly known under the brand name Adrucil.

How Supplied:

Contact supplier.

Indications for Fluorouracil:

Palliative management of carcinoma of the colon, rectum, and stomach.

Adult Dose for Fluorouracil:

Give by IV inj. 12mg/kg once daily for 4 successive days; max 800mg/day. If no toxicity is observed, 6mg/kg are given on the 6^th, 8^th, 10^th, and 12^th days unless toxicity occurs. Maintenance therapy: repeat dosage of 1^st course every 30 days after the last day of the previous course of treatment; or give a maintenance dose of 10–15mg/kg per week as a single dose; max: 1g/week. Poor risk patients: see literature for dose adjustments.

Children's Dose for Fluorouracil:

Not recommended.

Pharmacological Class:

Antimetabolite.

Contraindications:

Poor nutritional state. Depressed bone marrow function. Potentially serious infections.

Warnings/Precautions:

Narrow margin of safety; monitor for toxicity. Consider hospitalization for 1^st course. History of high-dose pelvic irradiation. Previous use of alkylating agents. Widespread involvement of bone marrow by metastatic tumors. Renal or hepatic impairment. Discontinue if signs of toxicity appear (eg, stomatitis, esophagopharyngitis, leukopenia, intractable vomiting, diarrhea, GI ulceration or bleeding, thrombocytopenia, hemorrhage). Monitor WBCs with differential before each dose. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Potentiated by leucovorin.

Adverse Reactions:

Stomatitis, esophagopharyngitis, GI upset, anorexia, leukopenia, alopecia, dermatitis, hand-foot syndrome; others.

Note:

Testing considerations: TS (thymidylate synthase), MSI (microsatellite instability), DPD (dihydropyrimidine dehydrogenase). Formerly known under the brand name Adrucil.

How Supplied:

Contact supplier.

Indications for Fluorouracil:

Palliative management of carcinoma of the pancreas.

Adult Dose for Fluorouracil:

Give by IV inj. 12mg/kg once daily for 4 successive days; max 800mg/day. If no toxicity is observed, 6mg/kg are given on the 6^th, 8^th, 10^th, and 12^th days unless toxicity occurs. Maintenance therapy: repeat dosage of 1^st course every 30 days after the last day of the previous course of treatment; or give a maintenance dose of 10–15mg/kg per week as a single dose; max: 1g/week. Poor risk patients: see literature for dose adjustments.

Children's Dose for Fluorouracil:

Not recommended.

Pharmacological Class:

Antimetabolite.

Contraindications:

Poor nutritional state. Depressed bone marrow function. Potentially serious infections.

Warnings/Precautions:

Narrow margin of safety; monitor for toxicity. Consider hospitalization for 1^st course. History of high-dose pelvic irradiation. Previous use of alkylating agents. Widespread involvement of bone marrow by metastatic tumors. Renal or hepatic impairment. Discontinue if signs of toxicity appear (eg, stomatitis, esophagopharyngitis, leukopenia, intractable vomiting, diarrhea, GI ulceration or bleeding, thrombocytopenia, hemorrhage). Monitor WBCs with differential before each dose. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Potentiated by leucovorin.

Adverse Reactions:

Stomatitis, esophagopharyngitis, GI upset, anorexia, leukopenia, alopecia, dermatitis, hand-foot syndrome; others.

Note:

Testing considerations: TS (thymidylate synthase), MSI (microsatellite instability), DPD (dihydropyrimidine dehydrogenase). Formerly known under the brand name Adrucil.

How Supplied:

Contact supplier.